Comment on 'Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis': reply from author

A. Affleck (Lead / Corresponding author), A. Goudie, R. Smith

    Research output: Contribution to journalLetter

    Abstract

    There appears to be some overlap in pathogenetic mechanisms between psoriasis and idiopathic pulmonary fibrosis e.g. raised IL-17; indeed, the possibility of a restrictive form of psoriatic lung disease has been raised although it appears to be rare. Patients with psoriasis may be at increased risk of developing interstitial lung disease (most commonly idiopathic pulmonary fibrosis) independent of previous or concomitant exposure to immunosuppressant therapy. This article is protected by copyright. All rights reserved.

    Original languageEnglish
    Pages (from-to)593-594
    Number of pages2
    JournalClinical and Experimental Dermatology
    Volume44
    Issue number5
    Early online date24 Apr 2019
    DOIs
    Publication statusPublished - 1 Jul 2019

    Fingerprint

    Idiopathic Pulmonary Fibrosis
    Psoriasis
    Methotrexate
    Interleukin-17
    Interstitial Lung Diseases
    Immunosuppressive Agents
    Lung Diseases
    Therapeutics

    Keywords

    • Humans
    • Idiopathic Pulmonary Fibrosis
    • Immunosuppressive Agents
    • Methotrexate
    • Psoriasis

    Cite this

    @article{37d76ada850a4e7e88e84ea1e049388a,
    title = "Comment on 'Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis': reply from author",
    abstract = "There appears to be some overlap in pathogenetic mechanisms between psoriasis and idiopathic pulmonary fibrosis e.g. raised IL-17; indeed, the possibility of a restrictive form of psoriatic lung disease has been raised although it appears to be rare. Patients with psoriasis may be at increased risk of developing interstitial lung disease (most commonly idiopathic pulmonary fibrosis) independent of previous or concomitant exposure to immunosuppressant therapy. This article is protected by copyright. All rights reserved.",
    keywords = "Humans, Idiopathic Pulmonary Fibrosis, Immunosuppressive Agents, Methotrexate, Psoriasis",
    author = "A. Affleck and A. Goudie and R. Smith",
    note = "This article is protected by copyright. All rights reserved.",
    year = "2019",
    month = "7",
    day = "1",
    doi = "10.1111/ced.13993",
    language = "English",
    volume = "44",
    pages = "593--594",
    journal = "Clinical and Experimental Dermatology",
    issn = "0307-6938",
    publisher = "Wiley",
    number = "5",

    }

    Comment on 'Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis' : reply from author. / Affleck, A. (Lead / Corresponding author); Goudie, A.; Smith, R.

    In: Clinical and Experimental Dermatology, Vol. 44, No. 5, 01.07.2019, p. 593-594.

    Research output: Contribution to journalLetter

    TY - JOUR

    T1 - Comment on 'Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis'

    T2 - reply from author

    AU - Affleck, A.

    AU - Goudie, A.

    AU - Smith, R.

    N1 - This article is protected by copyright. All rights reserved.

    PY - 2019/7/1

    Y1 - 2019/7/1

    N2 - There appears to be some overlap in pathogenetic mechanisms between psoriasis and idiopathic pulmonary fibrosis e.g. raised IL-17; indeed, the possibility of a restrictive form of psoriatic lung disease has been raised although it appears to be rare. Patients with psoriasis may be at increased risk of developing interstitial lung disease (most commonly idiopathic pulmonary fibrosis) independent of previous or concomitant exposure to immunosuppressant therapy. This article is protected by copyright. All rights reserved.

    AB - There appears to be some overlap in pathogenetic mechanisms between psoriasis and idiopathic pulmonary fibrosis e.g. raised IL-17; indeed, the possibility of a restrictive form of psoriatic lung disease has been raised although it appears to be rare. Patients with psoriasis may be at increased risk of developing interstitial lung disease (most commonly idiopathic pulmonary fibrosis) independent of previous or concomitant exposure to immunosuppressant therapy. This article is protected by copyright. All rights reserved.

    KW - Humans

    KW - Idiopathic Pulmonary Fibrosis

    KW - Immunosuppressive Agents

    KW - Methotrexate

    KW - Psoriasis

    UR - http://www.scopus.com/inward/record.url?scp=85066050577&partnerID=8YFLogxK

    U2 - 10.1111/ced.13993

    DO - 10.1111/ced.13993

    M3 - Letter

    C2 - 31017679

    VL - 44

    SP - 593

    EP - 594

    JO - Clinical and Experimental Dermatology

    JF - Clinical and Experimental Dermatology

    SN - 0307-6938

    IS - 5

    ER -